Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.
Manraj Singh SraArchana SasiAtul BatraSameer BakhshiShuvadeep GangulyPublished in: JCO global oncology (2024)
The combination of adjuvant abemaciclib or ribociclib with letrozole is not cost-effective for HR+/HER2- EBC in India in either the BC or WC scenario.
Keyphrases